Delivery Order SPE2DB24D2100-SPE2DB25FBBVC
Award Date
1/21/25
Potential Completion Date
2/11/25
Potential Value
$24K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $46,236.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a critical prescription medication, to support DLA's medical supply chain. The contract has an ultimate completion date of September 20, 2024 and is a Firm Fixed Price Delivery Order. This award is likely part of a larger Indefinite Delivery Contract (IDC) that...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $24,038.58, is a delivery order for the supply of OCREVUS 300 MG/1 ML 1S, a specialty medication. The contract is a firm fixed-price delivery order with a completion date of January 16, 2025. It is not associated with a set-aside program. AmerisourceBergen holds a significant...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract has a ceiling value of $54,395.32 and a completion date of October 10, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $11,559.04 and is a Delivery Order awarded by the Defense Logistics Agency (DLA) Troop Support Medical. It is a Firm Fixed Price contract with an ultimate completion date of August 30, 2024. The contract is not set aside and is part of AmerisourceBergen's Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $47,834.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a completion date of January 8, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,077.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a period of performance ending on January 28, 2025. The contract was not set aside for any specific business category. In addition to this delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office Division. The contract, valued at up to $115,590.40, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. This is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of OCREVUS (ocrelizumab) 300 mg/10 ml vials. The $46,236.16 firm fixed-price delivery order has an ultimate completion date of October 18, 2024. The award is not associated with a set-aside program. This contract is likely part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support...
This contract award to Amerisourcebergen Drug Corp (a major pharmaceutical distributor) is a Delivery Order (SPE2DB24FD7Z1) from the Defense Logistics Agency (DLA) Troop Support Medical. It is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication, with a ceiling value of $115,590.40. The award has a period of performance through October 3, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4564133145 OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. The contract has a ceiling value of $46,236.16 and runs through April 22, 2024. This delivery order falls under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp with a potential value of up to $999,999,999.00 and a...